Ginkgo Bioworks (DNA) Competitors

Ginkgo Bioworks (NYSE:DNA) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Do institutionals and insiders believe in DNA or SYRE?

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 9.7% of Ginkgo Bioworks shares are held by insiders. Comparatively, 6.2% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the media refer more to DNA or SYRE?

In the previous week, Ginkgo Bioworks and Ginkgo Bioworks both had 13 articles in the media. Ginkgo Bioworks' average media sentiment score of 0.86 beat Spyre Therapeutics' score of 0.08 indicating that Ginkgo Bioworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	5 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility & risk, DNA or SYRE?

Ginkgo Bioworks has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.9, indicating that its share price is 190% more volatile than the S&P 500.

Does the MarketBeat Community prefer DNA or SYRE?

Ginkgo Bioworks received 8 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 46.15% of users gave Ginkgo Bioworks an outperform vote.

Company	Underperform	Outperform
Ginkgo Bioworks	Outperform Votes 24 46.15%	Underperform Votes 28 53.85%
Spyre Therapeutics	Outperform Votes 16 100.00%	Underperform Votes No Votes

Which has stronger valuation & earnings, DNA or SYRE?

Spyre Therapeutics has lower revenue, but higher earnings than Ginkgo Bioworks. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$251.46M	1.41	-$892.87M	-$13.08	-0.49
Spyre Therapeutics	$890K	1,589.13	-$338.79M	-$7.47	-3.68

Do analysts recommend DNA or SYRE?

Ginkgo Bioworks currently has a consensus price target of $4.58, indicating a potential downside of 28.40%. Spyre Therapeutics has a consensus price target of $48.57, indicating a potential upside of 76.62%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Spyre Therapeutics is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	3 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.60
Spyre Therapeutics	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is DNA or SYRE more profitable?

Spyre Therapeutics has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -298.78%. Ginkgo Bioworks' return on equity of -58.54% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-298.78%	-58.54%	-34.24%
Spyre Therapeutics	N/A	-210.01%	-44.40%

Summary

Spyre Therapeutics beats Ginkgo Bioworks on 10 of the 17 factors compared between the two stocks.